VP22, a structural protein from herpes simplex virus type I, exhibits the unique property of intercellular trafficking. This protein is exported from primary expressing cells and subsequently imported into neighbouring cells. This property is conserved when VP22 is genetically fused to a protein, making it a promising tool to enhance the delivery of a gene product. We chose to study the intercellular transport and biological effect of a fusion protein between the putative tumour suppressor gene p27
Introduction
One of the major hurdles in the field of gene therapy remains the low efficiency of gene transfer, regardless of the type of vector used. To counteract this inability to deliver a gene product to a sufficiently high percentage of cells, the use of voyager proteins such as VP22 might be a promising alternative.
VP22 is a major protein of the herpes simplex virus-1 tegument, a region located between the envelope and the capsid of the virus. 1 The exact role of this protein in the virus life cycle is poorly understood, but it has been demonstrated recently that VP22 is able to transport mRNA to the uninfected cells for expression prior to viral infection. 2 However, VP22 exhibits the unusual property of intercellular spread. After introduction of the VP22 gene by microinjection or transfection, the VP22 protein is exported from transfected cells via a Golgiindependent pathway. After secretion, VP22 can be imported very efficiently into the neighbouring cells via a poorly understood mechanism. In primary synthetizing cells, VP22 can be found in the cytoplasm and in the nucleus, whereas in the neighbouring cells it accumulates mainly in the nucleus. 3 Furthermore, VP22 retains its trafficking ability when genetically fused to an effector protein like the green fluorescent protein (GFP). [3] [4] [5] [6] [7] Thus, linkage to VP22 has permitted to enhance the biological activity of several proteins such as the tumour suppressor p53 8, 9 or the products of the suicide genes thymidine kinase 10, 11 and cytosine deaminase. 12 It was also used to deliver functional Flp recombinase 13 and to carry SV40 large T antigen to induce cell cycle reentry in terminally differentiated muscle cells.
14 As a result of its spreading property, VP22 has also been used as an adjuvant in DNA vaccination assays. Fusion with VP22 was shown to increase the cellular and humoral immune response to proteins like YFP 15 or the human papilloma virus E7 antigen. 16 Despite those encouraging results, the use of VP22 as a cargo protein remains controversial. Fang and colleagues did not observe significant intercellular spreading of a VP22-GFP fusion in cultured mammalian cells 17 , and another study with the same fusion suggested that GFP was not functional in live recipient cells. 4 It has even been suggested that VP22 nuclear homing in living cells is an experimental artefact.
with poor prognosis in several malignancies like breast cancer. 21 In this regard, overexpression of p27 Kip1 via gene therapy might be a new possible treatment for human malignancies. Indeed, adenovirus-mediated overexpression of p27 Kip1 was associated with a cell cycle arrest in several human breast, brain and lung cancer cell lines. [22] [23] [24] In this study, we show that VP22 alone is able to spread efficiently between cells after gene transfer in every cell line tested. Cellular localization of VP22 and P27VP22 is mainly nuclear. Our results also indicate that a P27VP22 chimeric protein retains the trafficking ability of VP22 and the biological activity of p27 Kip1 . P27VP22 gene transfer demonstrated a stronger antiproliferative activity than p27
Kip1 gene transfer in vitro and in an in vivo model of human tumour xenografts in nude mice.
Results

VP22 can traffic between cells in vitro
We first analysed the trafficking properties of VP22 alone. COS7 cells were transfected with pAP85 H expressing the full-length VP22 tagged with an HAepitope or with peGFP-C1 encoding for GFP. Two days later, detection of GFP-positive cells by cytofluorimetry indicated that the transfection efficiency was approximately 18% (Figure 1a) , while almost 99% of the cells were positively stained with an anti-HA antibody indicating the presence of VP22. This strongly suggested that the VP22 protein was secreted by the 18% transfected cells and then entered virtually all the surrounding cells.
This phenomenon was confirmed using another technique of detection in the SAOS-2 cell line. After transfection with pAP85 H encoding VP22, observation of the cells immunolabelled with an anti-HA (Figure 1b) or an anti-VP22 (data not shown) antibody confirmed that virtually all the SAOS-2 cells were positive for VP22. When looking in more detail the intracellular localization of VP22, we very often observed large cells containing nuclear and cytoplasmic VP22 described by Elliott and O'Hare 3 as the transfected cells, serving as a reservoir for the dissemination of VP22 into the nucleus of the surrounding cells. No positive staining was obtained when cells were transfected with the empty vector pCDNA3. When the same experiment was performed after cotransfection of pAP85 H and pEGFP-C1 (in a ratio of 1/5 w/w), only a few double transfected cells were detected (Figure 1c) , while again the vast majority of the cells were positive for VP22.
In order to rule out the possibility that VP22's spreading is an artefact because of the fixation method, we performed an additional experiment in which two cell lines were mixed before or after fixation (Figure 1d ). In the first set-up, Saos2 cells were transfected with pAP85 H. The following day, BalbC 3T3 cells were added to the transfected Saos2 cells and incubated for 24 h (CP for Co-Plating). The cells were then fixed and VP22 detected by immunostaining as usual. BalbC 3T3 cells were easily detected after the Hoechst staining since their nuclei were punctuated. As expected, we observed that virtually all the BalbC 3T3 cells were positive for VP22, indicating that VP22 has been transferred from the Saos2 to the BalbC cells. In the following experiment, the transfected Saos2 cells and the untransfected BalbC cells were resuspended, fixed with 0.5% paraformaldehyde, mixed and immunostained for VP22 (F+M for Fixed then Mixed). We also performed the same experiment, but we first mixed the cells and then fixed them immediately (M+F for Mixed then Fixed). Results indicate that only Saos2 cells were positive for VP22 in both cases. This demonstrated that the spreading did not occur on fixed cells.
The spreading of VP22 was independent of the cell line. VP22's trafficking was evaluated in nine different cell lines using flow cytometry. Two days after transfection, the mean number of positive cells (Table 1) ranged from 76% (TSA cells) to 93% (H322 cells) while the transfection efficiency (measured by transfection with pGFP) varied from 18 to 45%. These results indicate that VP22 is able to traffic efficiently from cell to cell in every tested cell line.
VP22 can ferry p27
kip1 genetically fused at its N-term extremity
We were next interested in testing the trafficking ability of a fusion between the cell cycle inhibitor p27
Kip1 and VP22. In this regard, p27
Kip11 cDNA was fused at the Nterminal side of HA-tagged VP22 cDNA, resulting in plasmid pNDB23 encoding a P27VP22 fusion protein.
Correct expression of the fusion protein was monitored by Western blotting. In transiently transfected SAOS2 cells, an anti-Ha antibody detected the full-length P27VP22 fusion protein (Figure 2a ) at its expected size (approximately 62 kDa) as well as the HA-tagged VP22 (B40 kDa) and HA-tagged p27 Kip1 (B25 kDa). Analysis of the same extracts using an anti-VP22 antibody ( Figure  2b) showed expression of the full-length P27VP22 as well as two truncated products. One product had the molecular weight of VP22, indicating a cleavage between the two partners. The other product appeared slightly larger than p27 Kip1 , suggesting another clipping in the Nterminal extremity of VP22. An anti-p27 Kip1 antibody (data not shown) also detected these cleavage products, together with the full-length P27VP22.
To investigate the trafficking property of the fusion protein, SAOS2 cells were transfected with pNDB23 or P27HA (encoding a C-terminal HA-tagged p27 Kip1 ), and the spreading was quantified using flow cytometry analysis after immunolabelling with the anti-HA antibody. The results of a representative experiment (Figure 3a) indicate that whereas approximately 40% of the cells were directly transfected (estimated with detection of GFP fluorescence), more than 93% of the cells were positively stained for the presence of P27VP22 2 days after transfection. This phenomenon was confirmed using indirect immunofluorescence on SAOS2-transfected cells (Figure 3b protein can be found in surrounding cells. Therefore, the fusion protein P27VP22 seems to have the same spreading abilities as VP22 alone.
The P27VP22 fusion protein is biologically active
We then determined whether p27
Kip1 fused to VP22 conserved its biological activity. We first evaluated the functionality of P27VP22 by testing its ability to inhibit the kinase activity of the cyclineA/E-CDK2 complexes, a known target of p27 Kip1 . Equal amounts (200 mg) of protein extracts from H322-transfected cells were immunoprecipitated with an anti-CDK2 antibody, and a histone H1 phosphorylation assay was performed. Results ( Figure 4a ) indicated that, like p27 Kip1 , P27VP22 extracted from transfected cells was able to inhibit histone H1 phosphorylation. This result strongly suggested that p27
Kip1 remained functional when fused with VP22 even if this test did not discriminate between the fusion protein coming from the producing cell and the one which diffuses.
To evaluate the effect on cell growth, we first performed a proliferation assay on H322 cells. Results (Figure 4b) showed that transient transfection of p27 Kip1 decreased the total cell proliferation of 27% (when compared to the empty vector-transfected cells) while P27VP22 induced a dramatic inhibition of 49%. VP22 alone did not affect significantly the cell proliferation.
To confirm these results, we developed a special clonogenicity test (see Methods) to compare the antiproliferating activity of p27 Kip1 and P27VP22. MCF7 cells were cotransfected with vectors encoding p27
Kip1 , P27VP22 or VP22 in the presence of an excess of pCDNA3, then selected for 10 days with G418 and Antitumour activity of P27VP22 D Zavaglia et al counted. The results obtained (Figure 4c ) revealed that cotransfection of pCDNA3/P27VP22 had a significantly (Po0.005) better antiproliferative activity than that of pCDNA3/p27 Kip1 . In addition, cotransfection of pCDNA3/VP22 indicated that VP22 expression is not toxic (data not shown). Similar results were obtained with SAOS2 and H322 cell lines (data not shown).
Since both the p27 Kip1 and P27VP22 proteins have an inhibitory activity in vitro (Figure 4a ), all these results suggest that the stronger effect on proliferation obtained with P27VP22 only reflects the ability of VP22 to shuttle p27
Kip1 in a higher number of cells.
P27VP22 gene transfer inhibits tumour growth
To study whether P27VP22 could keep its activity in vivo, human H322 tumour cells were implanted sub-cutaneously in nude mice. Two intratumoural injections per week of 10 mg naked DNA were performed on established tumours and their volumes were measured once a week for 63 days (Figure 5a ). Tumours treated with pCMV-Luc were used as control. At the end of the experiment, plasmid coding for p27 Kip1 did not have a significant effect on tumour growth when compared to plasmid coding for VP22 or luciferase. In contrast, plasmid encoding P27VP22 showed strong antiproliferative effect. Tumours were approximately twice smaller than those that received vector encoding p27
Kip1 only and were also significantly (Po0.05) smaller than tumours injected with vectors encoding VP22 or luciferase. These results demonstrate that the P27VP22 fusion is the only construction that induces significant tumour regression in vivo.
Immunohistochemistry was performed on tumour slices to study the pattern of expression of the different proteins in vivo. Analysis of pictures from representative slices (Figure 5b ) revealed that p27
Kip1 protein staining was mainly nuclear and always found in isolated individual cells. Conversely, VP22 and P27VP22 staining were similar. Both of them showed groups of positive cells with nuclear staining, with some cells in the group containing cytoplasmic staining. This pattern suggests that VP22 and P27VP22 are able to spread into the tumour mass and that this property is likely to explain the antitumour activity of P27VP22.
In order to demonstrate how P27VP22 gene transfer could induce this antiproliferative effect, we looked for the presence of infiltrating NK cells and monocytes using an anti-CD11b immunostaining. None of the tumours presented a significant increase in the number of CD-11b-positive cells, suggesting that the antitumour activity of P27VP22 was not involving a massive cell-mediated immunity (Figure 6a ). In addition, such a non-specific immune response would also be induced after transfection of VP22. Since VP22-treated tumours grew as fast as the controls, it is unlikely that cell-mediated immunity was involved in the P27VP22 antitumour activity.
Finally, we also measured the number of apoptotic cells using an anti-active form of caspase 3 immunostaining (Figure 6b ) and the number of proliferating cells using an anti-Ki67 antibody (data not shown). No significant differences were noticed using the anti-active form of caspase 3 among the different groups, suggesting that no massive cell death was induced. Anti-Ki67 staining was not informative because the tumours were too heterogeneous, presenting large areas of quiescent cells as well as large areas of dividing cells.
Discussion
In an attempt to bypass the low transduction efficiency of vectors available for cancer gene therapy protocols, we used the unique property of intercellular transport of the herpes virus protein VP22 to deliver the p27 Kip1 cell cycle inhibitor to tumour cells.
Our study shows that VP22 is able to spread efficiently in every cell line tested and that this ability is retained by a P27VP22 fusion. Moreover, we show that this fusion protein is functional and that P27VP22 gene transfer induces a stronger antiproliferative effect than p27 Kip1 gene transfer in vitro and in vivo.
Detection and quantification of intercellular trafficking in vitro have raised several issues and contradictory (encoding the neo gene product) alone or cotransfected with an excess of pCDNA3 and p27HA or pNDB23 encoding P27VP22. Cells were then selected for 10 days with G418 and the final number of living cells was estimated by methylene blue staining (see Methods). NT: Not transfected. Experiment was performed three times with three wells per group each time. **Significant difference between P27VP22 and P27 (po0.01) using a t-test. P27 stands for p27 Kip1 .
Antitumour activity of P27VP22 D Zavaglia et al results. Most of these studies were using a GFP-VP22 fusion and the main problem seemed to concern the method of fixation. Some authors claimed that efficient spreading can only be detected after methanol fixation, with the damaging effect of methanol on membranes being responsible for the nuclear uptake of VP22 by neighbouring cells. 4, 25, 26 This phenomenon could lead to an artefactual VP22 nuclear homing 18 not observed with paraformaldehyde fixation. 25 Conversely, other reports showed that efficient transport can be observed with both fixation methods 5 and in living cells. 7 It is noteworthy that we were able to detect intercellular trafficking of VP22 and P27VP22 using paraformaldehyde (Figures 1 and 3 ; cytometry) and methanol fixation (Figures 1 and 3; immunofluorescence) . We found out that localization of VP22 (or P27VP22) in recipient cells is mainly nuclear and does not depend on the fixation method. Moreover, we assessed the possibility of a fixation-induced artefactual spreading of VP22. In two different experiments (Figure 1d ) where VP22-transfected SAOS2 cells and untransfected BalbC 3T3 cells were either mixed then fixed or fixed separately then mixed, we did not observe artefactual spreading of VP22 towards untransfected cells during the process of fixation and permeabilization of the cells for immunostaining. Together with the enhanced biological activity obtained with P27VP22 in vitro and in vivo, our results demonstrate that VP22 spreading is not an experimental artefact.
Two main issues in this study were the choice of the fusion and the clipping of the fusion protein. We chose to study only the N-terminal fusion because it was shown In vivo spreading of P27VP22. Tumours were excised from nude mice 24 h after the last intratumoural injection of 10 mg DNA vector encoding P27, P27VP22 or VP22 as indicated. Five micrometer tumour slices were then immunostained with anti-HA antibody and nuclei were counterstained with haematoxylin staining. P27 stands for p27 Kip1 .
Antitumour activity of P27VP22 D Zavaglia et al that the C-terminal extremity of VP22 is essential for cellto-cell transport. 3, 27 Furthermore, our works on a VP22-P53 fusion (data not shown) indicated that this Cterminal fusion was unable to spread efficiently. This was recently confirmed in a study using a VP22-CD (cytosine deaminase) protein. 12 This fusion was not able to spread, whereas a CD-VP22 fusion showed efficient intercellular transport. The second persistent problem remains the cleavage of fusion proteins. Analysis of protein expression (Figure 2) showed that beside expression of the full-length P27VP22 protein, a truncated product always appears Figure 6 No infiltration of NK or monocytes cells or massive induction of apoptosis were observed after treatment of the tumours by P27VP22. Tumours were excised from nude mice 24 h after the last intratumoural injection of 10 mg DNA vector encoding Luc, P27, P27VP22 or VP22 as in Figure 5 . Five micrometer tumour slices were then immunostained with anti-CD11b antibody (a) or an anti-active form of caspase 3 (b) and nuclei were counterstained with haematoxylin staining. P27 stands for p27 Kip1 .
Antitumour activity of P27VP22 D Zavaglia et al when immunoblotting is performed with an anti-VP22 (Figure 2b ) or an anti-p27 Kip1 (data not shown) antibody. We already observed this phenomenon with a P21-VP22 and a P53-VP22 fusion (unpublished work), and other groups also described this pattern when working with N-terminal fusions. 8, 10, 12 Usually, these experiments reveal a cleavage product at a size slightly superior to the size of the protein fused to VP22. Another cleavage can also appear at the junction between VP22 and its partner. Our results thus confirm the susceptibility to cleavage for fusions at the N-terminal extremity of VP22 as well as the ability of anti-tag antibodies to detect only full-length fusion proteins. Actually, we do not know if these cleavages happen during synthesis, secretion and diffusion or after internalization by the surrounding cells. If these clippings occur before internalization of the protein, they will decrease the spreading efficiency. Precise identification of these sensitive sites could help to overcome this problem. Site-directed mutagenesis in the VP22 nucleic sequence might increase the resistance to cleavage.
Nevertheless, intercellular trafficking was obvious with P27VP22 and its gene transfer induced a stronger cell growth inhibition than p27
Kip1 gene transfer in proliferation (Figure 4b ) and clonogenicity assays ( Figure  4c ). VP22 displayed very weak toxicity in these experiments, indicating that the increased activity is solely due to the transport properties of VP22. Furthermore, functionality of P27VP22 was demonstrated in a histone H1 kinase assay. Similar to p27
Kip1 , the P27VP22 protein is able to induce an inhibition of CDK2 activity. This result reinforces the idea that the redistribution of p27 Kip1 to a higher number of cells is responsible for the enhanced activity obtained with P27VP22.
Increase in the antiproliferative activity is significant and can also be observed in vivo. Previous studies had successfully used a TK-VP22 producing retrovirus 10 and a P53-VP22 adenoviral vector 9 to treat in vivo preestablished tumours. In this study, we opted for a naked DNA delivery method to confirm the efficiency of VP22-mediated delivery in vivo. Intratumoural injections of the P27VP22 plasmid slowed down tumour progression more efficiently than injections of the p27 Kip1 plasmid (Figure 5a ). Two complete tumour regressions were obtained with P27VP22, in spite of the very low transduction efficiency of naked DNA transfer in vivo. Even if the in vivo activity observed with P27VP22 was obtained in nude mice, we tested the possibility that an immune reaction triggered by VP22 could be responsible for the inhibition of tumour growth. Immuno-histochemical analysis of tumour slices (Figure 5b) suggests that VP22 and P27VP22 can spread in vivo but no major infiltration of monocytes, granulocytes or NK lymphocytes was obvious after HES staining or an anti-CD11-b immunolabelling of the tumour sections (Figure 6a) . Injection of the plasmid encoding for VP22 alone did not affect the tumour progression (Figure 5a ), suggesting that VP22 per se is unable to trigger an efficient immune response in nude mice. Thus, the antitumoural activity of P27VP22 is certainly reflecting a p27
Kip1 -mediated inhibition of proliferation that occurs in a larger number of tumour cells thanks to VP22 spreading properties. Nonetheless, it is known that VP22 is immunogenic. 28, 29 This could influence its ability to ferry therapeutic proteins in animals with a normal immune system, but it could also increase the antitumour activity by directing the immune response towards the tumour cells presenting the VP22 fusion protein.
In conclusion, this study provides the first results of a non-virally delivered VP22 fusion in vitro and in vivo and demonstrates the usefulness of VP22 to improve biological activity via intercellular delivery of a functional protein.
Materials and methods
Cell lines
COS-7 and HeLa cells were grown in DMEM+10% FBS+0.5% PS (penicilline-streptomycine). H358, H322; BalbC 3T3 and A549 cells were cultured in RPMI+10% FBS+0.5% PS. SAOS2 cells were grown in McCoy's+10% FBS+0.5% PS. MCF7 cells were cultured in DMEM+10% FBS+0.5% PS+1 mg/ml insulin. TS/Apc and B16 cells were grown in RPMI+10% FBS+0.5% PS+2.5 Â 10 À5 M bmercaptoethanol. All cell lines were incubated at 371C with 5% CO 2 .
Plasmids
Plasmids pAP85H (encoding an HA-tagged full-length VP22), P27HA (encoding an HA-tagged p27 Kip1 ) and pNDB23 (encoding a P27VP22 in frame fusion) were kindly provided by Neil Brewis (Marie Curie Research Institute, Oxted, UK). These three vectors were derived from pcDNA1.Amp (Invitrogen, Groningen, Netherlands) with expression driven by a CMV promoter. Vector peGFP-C1 encoding GFP was obtained from Clontech Laboratories (Palo Alto, CA, USA). Plasmid pCMV-Luc expressing luciferase was kindly provided by Dr Franc¸ois Berger (INSERM U318, France). Empty vector pcDNA3 (bearing G418 resistance) was from Invitrogen.
Transfection
For Facscan analysis, cells were plated at 4 Â 10 6 cells/ 10 cm Petri dish and transfected 24 h later with 15 mg DNA complexed with polyethyleneimine (L-PEI Euromedex, Mundolsheim, France) according to the manufacturer's instructions.
For immunofluorescence, cells were plated on coverslips into 24-well trays at a density of 10 5 cells/well and transfected 24 h later with 1.5 mg DNA complexed with Fugene6 s (Roche Diagnostics, Meylan, France) according to manufacturer's instructions.
For the clonogenecity test, MCF7 cells were plated into six well trays at a density of 2 Â 10 5 cells/well and transfected 24 h later with a total of 4 mg DNA complexed with Fugene6 s . When cotransfections were performed, an excess of pcDNA3 was used at a ratio of 4/1.
Flow cytometry
Two days after transfection, cells were trypsinized and fixed on ice for 5 min with 0.5% paraformaldehyde. After three washes in PBS/BSA 0.1%, primary monoclonal antibody anti-HA (Babco, Richmond, CA, USA) diluted at 1/500 (in PBS with 0.1% BSA and 500 mg/ml digitonin) was added for 2 h at room temperature (RT). After two washes, cells were incubated for 45 min at RT with secondary antibody Alexa TM 488 (Molecular Probes,
Leiden, Netherlands) at 1/350 (in PBS with 0.1% BSA and 500 mg/ml digitonin), then washed, centrifuged and the pellet was resuspended in 1 ml PBS. Cells were then analysed using a flow cytometer (Facsan, Becton Dickinson, Pont de Claix, France) with the Cell Quest software. Cells transfected with peGFP-C1 were trypsinized, washed and directly suspended in PBS for Facscan analysis. Graphs were obtained with ProCyt software (Philippe Albert, INSERM U309, France).
Immunofluorescence
Forty-eight hours post-transfection, cells were washed in PBS, fixed in cold methanol for 10 min at RT, then permeabilized with 0.2% Triton for 1 h 30 min at RT. After washing in PBS, saturation for 30 min in 5% non-fat milk at RT, cells were incubated with monoclonal anti-HA (Babco) diluted at 1/1000 (in 1% non-fat milk) for 2 h at RT. After three washes, secondary antibody Alexa TM 568 (Molecular Probes) at 1/750 was added for 1 h at RT. Cells were then washed three times with 1 time in PBS/ Hoescht at 1/500 to stain the DNA. Coverslips were mounted in Moeviol (Sigma, Saint Quentin Fallavier, France) and slides examined using an Olympus AX 70 epifluorescence microscope.
Coplating and fixation experiments
SAOS2 cells (5 Â 10 5 ) were plated in six well plates and transfected 24 h later with 4.5 mg pAP85H encoding VP22 or control vector pCDNA3.1 using Fugene6 s transfection reagent. For coplating experiments, 1 Â 10 6 BalbC 3T3 cells were added to the transfected SAOS2 cells 24 h after transfection. Cells were cocultured for 24 h, then fixed with 0.5% PFA for 5 min on ice and processed for immunoflorescence using a primary anti-HA antibody and a secondary antibody Alexa TM 568 diluted in PBS with 0.1% BSA and 500 mg/ml digitonin for permeabilization. Cells were mounted in Moeviol and slides examined using an Olympus AX 70 epifluorescence microscope.
For fixation experiments, SAOS2 cells were trypsinized 48 h after transfection and two different treatments were performed: in one experiment (Mix then Fix), 1 Â 10 6 BalbC 3T3 cells were mixed with the SAOS2 cells and immediately fixed for 5 min on ice with 0.5% PFA, then processed for immunofluorescence as above. In the other experiment (Fix then Mix), SAOS2 cells and 1 Â 10 6 BalbC 3T3 cells were fixed separately with 0.5% PFA for 5 min on ice, then mixed together and processed for immunofluorescence as above.
Western blot analysis
Cells were washed in PBS, trypsinized and proteins were extracted with RIPA lysis buffer (Tris-Hcl 50 mM pH 7.5, NaCl 150 mM, 0.5% sodium deoxycholate, 1% Nonidet P-40, 0.1% SDS, 0.5 mM phenylmethylsulphonyl fluoride, 10 mg/ml leupeptin, 10 mg/ml aprotinin and 10 mg/ml pepstatin) for 30 min on ice. Cell lysates were then subjected to polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK). After blocking non-specific binding sites for 30 min with 5% non-fat milk in TPBS (PBS, 0.1% Tween 20) at RT, the membrane was incubated overnight at +41C with monoclonal mouse anti-HA antibody (Babco) or polyclonal rabbit anti-VP22 serum (kindly provided by Neil Brewis, MCRI, UK) diluted in TPBS. Immunoreactive proteins were visualized using horseradish peroxydaseconjugated anti-mouse or anti-rabbit antibodies (diluted in TPBS) for 45 min at RT followed by enhanced chemoluminescence (ECL, Amersham).
Immunoprecipitation and histone H1 kinase assay H322 cells were seeded at a density of 4 Â 10 6 cells/Petri dish and transfected 24 h later with 15 mg DNA complexed with Fugene6 s (Roche Diagnostics) according to the manufacturer's instructions. Three days later, the cells were washed three times with PBS, resuspended in lysis buffer (150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 50 mM Tris-HCl pH 7.4, 1% Triton 100X, 0.2 mM Na 3 VO 4 , 0.5% Nonidet P40, 0.1 mM PMSF, 2.5 mg/ml pepstatin, 10 mg/ml aprotinin, 5 mg/ml leupeptin), incubated on ice for 30 min and centrifugated for 20 min at 10 000 g. Protein concentration was adjusted to 200 mg in 200 ml NET buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.5, 0.1% NP40, 1 mM EDTA pH 8, 0.25% gelatin, 0.02% sodium azide) supplemented with protease inhibitors before use and incubated overnight at +41C with 2 ml polyclonal anti-CDK2 antibody (BD Pharmingen). To each reaction, 1 mg of protein G sepharose beads was added and samples were incubated for 1 h at +41C with gentle rotation. After two washes in NET buffer, the beads were subjected to a final wash in kinase buffer (50 mM TrisHCl, pH 7.6, 10 mM MgCl 2 , 1 mM DTT). Ten ml aliquots were added to 40 ml of kinase buffer containing 50 mM ATP, 10 mCi 32 P ATP (3000 Ci/mmol) and 50 mg of histone H1 and incubated for 30 min at 301C. Samples were boiled in the presence of 50 ml SDS-PAGE loading buffer and subjected to electrophoresis on a 12% polyacrylamide gel. CDK2 activity was visualized by autoradiography.
Cell proliferation assay
Cells were seeded at a density of 80 000 cells/well in 24-well plates and transfected 24 h later with 1.5 mg DNA complexed with Fugene6 s (Roche Diagnostics). After incubation for 3 days at 371C, growth inhibition was evaluated by the WST-1 (Roche Diagnostics) colorimetric assay, based on the cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases in viable cells. Briefly, 200 ml of new medium then 20 ml of WST-1 were added to the cells. After incubation for 20 min at 371C, the stained solutions were transferred to a 96-well plate for measurement in a microtiter plate reader (Dynatech MR 5000) using a 450 nm filter.
Clonogenicity test
MCF7 cells were cotransfected with vectors encoding p27
Kip1 , P27VP22 or VP22 in the presence of an excess of pCDNA3. Twenty-four hours after transfection, the medium was changed and replaced with fresh medium containing 1 mg/ml G418. Selection lasted for 10 days with the medium changed every 3 days. At day 10, cells were washed three times with PBS, fixed with 100% ethanol for 15 min at RT and dried at least for 15 min at 371C. Cells were then stained with methylene blue (1% in 0.01 M borate buffer pH 8.5) for 15 min at RT. After extensive washes with water and drying for 30 min at 371C, staining was eluted with 0.1 N HCl, and 100 ml of each well was used to measure the OD (proportional to the number of cells) at 630 nm.
Antitumour activity of P27VP22 D Zavaglia et al
Since pCDNA3 is in excess, some cells will be transfected by pCDNA3 only and not by p27 Kip1 or P27VP22. We hypothesized that a cell receiving pCDNA3 would proliferate because pCDNA3 encodes for the neo gene product. A cell receiving both pCDNA3 and p27 Kip1 will be blocked in the cell cycle due to the effects of p27
Kip1 and thus will not proliferate. Finally, cells cotransfected by pCDNA3 and P27VP22 will also be blocked but, if the P27VP22 protein is able to spread towards other pCDNA3 bearing cells, a larger number of cells will not proliferate and the final number of clones will be lower than after a pCDNA3/p27
Kip1 cotransfection.
In vivo tumour treatments
Five-week-old female Swiss nude mice (Iffa Credo, Marcy l'Etoile, France) were injected subcutaneously with 20 Â 10 6 H322 (human bronchioalveolar carcinoma) cells. Four weeks later, all animals had small palpable tumours. Twice a week, intratumoural injections of 10 mg DNA (diluted into 150 ml of 5% glucose) were performed with insulin syringes (29 gauge, 0.5-inch needles) (Becton Dickinson). Tumour volume was measured every week using the formula Volume¼a Â b 2 Â 0.4 in which a and b are the larger and smaller diameters, respectively. Statistics were performed using GraphPad Prism s software.
Anti-HA immunohistochemistry
Twenty-four hours after the last DNA injection, tumours were excised and fixed in 3.7% formaldehyde for 4 h, then washed overnight in PBS before paraffin inclusion. Five micrometer paraffin slices were first treated 3 Â 5 min in toluene, 2 Â 5 min in 100% ethanol, 5 min in 95% ethanol and 5 min in water. Slides were then transferred in 200 ml water+7 ml 30% H 2 O 2 (to block endogenous peroxydases), then placed in Microstain Unmasker (Microm s , Francheville, France) buffer and submitted to four microwave (750 W) cycles of 5 min each. After cooling and washing in PBS, slices were blocked with 5% non-fat milk (in PBS) for 30 min. Mouse monoclonal anti-HA (Babco) antibody (1/500 in 1% nonfat milk) was added overnight at 41C in a wet atmosphere. The following day, slides were washed three times in PBS, then blocked for 10 minutes in 5% non-fat milk. Biotynilated secondary antibody (Biotin Donkey anti-mouse, Jackson Immunoresearch, West Grove, PA, USA) (1/500 in 1% non-fat milk) was added for 1 h at RT. After three washes, streptavidin/peroxydase complexes (ABC system from Dako, Trappes, France) were added for 30 min at RT. After three washes, slices were incubated with peroxydase substrate Novared TM (Vector Labs, Burlingame, CA, USA) for 3 min then washed in water. Slices were counterstained with haematoxylin (Merck Eurolab, Strasbourg, France) and dehydrated before mounting in Merkoglass s (Merck).
CD11b immunostaining
Samples of treated tumours were frozen in liquid nitrogen. Five micrometer frozen slices were fixed for 10 min in cold methanol and dried. After saturation with 5% non-fat milk (in PBS) for 30 min, rat monoclonal antimouse CD11b (Immunotech, Marseille, France) at 1/50 in 1% milk was added overnight at 41C. The following day, after three washes in PBS and 10 min blocking in 5% milk, peroxydase-conjugated rabbit anti-rat antibody (Dako) at 1/50 in 1% milk was added for 1 h at RT. After three washes, slices were incubated with peroxydase substrate Novared TM for 3 min then washed in water. Slices were counterstained with Haematoxylin and dehydrated before mounting in Merkoglass s .
Active caspase 3 immunostaining
Five micrometer fresh frozen slices obtained from treated tumours were fixed for 10 min in cold methanol and dried. After saturation with 5% BSA for 30 min, rabbit anti-human Caspase three Active (R&D Systems) at 1/ 5000 in BSA 1% was added overnight at 41C. The following day, after three washes in PBS and blocking for 10 min in BSA 5%, biotin-conjugated donkey anti-rabbit antibody (Jackson Immunoresearch) at 1/1250 in BSA 1% was added for 1 h at RT. After three washes in (TBS tris buffered saline: 0.05 M Tris/HCl; 0.15 M NaCl) at pH 7.6, alkaline phosphatase StreptABCompex (Dako) was added for 30 min at RT. After three washes in TBS, slices were incubated with Fast Red s substrate (Sigma), counterstained with hematoxylin and mounted in Mowiol s (Calbiochem, La Jolla, CA, USA).
Microscopy
Photographs were taken with an Olympus AX 70 microscope. Image acquisition and processing were performed using Visilog r Noesis software and Adobe Photoshop 5.0 (Adobe System, Seattle, WA, USA).
